Evaluate the Safety and Efficacy of CD33 CAR-T in Patients With R/R AML

Zhejiang University logo

Zhejiang University

Status and phase

Not yet enrolling
Phase 1

Conditions

AML

Treatments

Biological: CD33 CAR-T

Study type

Interventional

Funder types

Other

Identifiers

NCT05473221
BG-CT-22-002(CD33)

Details and patient eligibility

About

This is an open label, phase I study to assess the safety and efficacy of CD33 CAR-T in patients with relapsed and refractory acute myeloid leukemia

Enrollment

20 estimated patients

Sex

All

Ages

2 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All subjects must sign and date the Informed Consent before initiating any study specific procedures or activities;
  • Diagnosed as relapse/refractory (r/r) de novo or secondary acute myeloid leukemia (AML);
  • The expression of CD33 in AML blast is positive ;
  • The patient has recovered from the toxicity of previous treatment;
  • ECOG score ≤ 2 and expected survival period is not less than 3 months;

Adequate organ function defined as:

AST ≤3×ULN; ALT ≤3×ULN; Total bilirubin ≤1.5×ULN; Serum creatinine ≤1.5×ULN, or CCR≥60 mL/min; Hemoglobin ≥60g/L ; Indoor oxygen saturation ≥92%; LVEF≥45%;

  • Pregnancy testing: females of childbearing potential must have a negative serum or urine pregnancy test;
  • From the use of study drug to 2 years after treatment, males and female of childbearing potential must agree to use an effective method of contraception

Exclusion criteria

  • Diagnosis of acute promyelocytic leukemia;
  • History or presence of a CNS disorder;
  • HBsAg or HBcAb are positive; HCV 、HIV and Syphilis antibody are positive, CMV DNA in peripheral blood is more than≥500 copies /mL;
  • History of severe hypersensitivity reaction;
  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, New York Heart Association Class II or greater congestive heart failure, atrial fibrillation, or other clinically significant cardiac disease within 12 months before enrollment;
  • History of organ transplant surgery;
  • Required systemic application of immunosuppressive or other drugs;
  • Auto-SCT within the 3 months before enrollment;
  • Active autoimmune or inflammatory diseases of the nervous system (e.g., Guillain-Barre syndrome (GBS), amyotrophic lateral sclerosis (ALS)) and clinically active cerebrovascular diseases (e.g., cerebral edema, posterior reversible encephalopathy syndrome (PRES));
  • Requirement for urgent therapy due to ongoing or impending oncologic emergency (eg, leukostasis or tumor lysis syndrome (TLS)) ;
  • Presence or suspicion of a fungal, bacterial, viral, or other infection that is uncontrolled or requiring antimicrobials for management;
  • Live vaccine received within the ≤ 4 weeks before enrollment;
  • Persons with serious mental illness;
  • History of major surgical operations four weeks before enrollment;
  • History of alcoholism or substance abuse;
  • Was identified by the investigators as unsuitable to participate in the study

Trial design

20 participants in 1 patient group

CD33 CAR-T
Experimental group
Description:
Dose Escalation:After enrollment ,Participants complete the PBMC apheresis,then complete the Lymphocyte clearance,and then receive the dose climning test: 3×10e6/kg,6 ×10e6/kg,9×10e6/kg. Dose Expansion:Participants receive a single dose (at the MTD determined).
Treatment:
Biological: CD33 CAR-T

Trial contacts and locations

0

Loading...

Central trial contact

Mingming Zhang, MD; He Huang, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems